Abstract
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors. Three subtypes -- PPAR alpha, PPAR beta, and PPAR gamma -- have been identified and are differentially expressed in tissues. Originally, they were described as molecular regulators of lipid metabolism; recently, it has been shown that they are also involved in regulating the cell cycle and apoptosis in both normal and tumoral cells. In fact, some synthetic PPAR ligands are used to treat dyslipidemia, metabolic diseases, and type 2 diabetes. Here, we review the role of PPAR gamma (PPARγ) in tumor initiation and progression, emphasizing the relationship between this isoform and the cellular and molecular mechanisms involved in the antineoplastic effect of iodine on mammary cancer.
Keywords: Antineoplastic, apoptosis, iodine, iodolactone, mammary cancer,, peroxisome proliferator-activated receptor (PPAR), sodium-iodide symporter, prostate specific antigen, thiazolinidinedione, ciglitazone, Peroxisome proliferator response element, non-steroidal anti-inflammatory drugs
Current Cancer Drug Targets
Title: Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Volume: 11 Issue: 7
Author(s): R. E. Nunez-Anita, M. Cajero-Juarez and C. Aceves
Affiliation:
Keywords: Antineoplastic, apoptosis, iodine, iodolactone, mammary cancer,, peroxisome proliferator-activated receptor (PPAR), sodium-iodide symporter, prostate specific antigen, thiazolinidinedione, ciglitazone, Peroxisome proliferator response element, non-steroidal anti-inflammatory drugs
Abstract: Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors. Three subtypes -- PPAR alpha, PPAR beta, and PPAR gamma -- have been identified and are differentially expressed in tissues. Originally, they were described as molecular regulators of lipid metabolism; recently, it has been shown that they are also involved in regulating the cell cycle and apoptosis in both normal and tumoral cells. In fact, some synthetic PPAR ligands are used to treat dyslipidemia, metabolic diseases, and type 2 diabetes. Here, we review the role of PPAR gamma (PPARγ) in tumor initiation and progression, emphasizing the relationship between this isoform and the cellular and molecular mechanisms involved in the antineoplastic effect of iodine on mammary cancer.
Export Options
About this article
Cite this article as:
E. Nunez-Anita R., Cajero-Juarez M. and Aceves C., Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer, Current Cancer Drug Targets 2011; 11 (7) . https://dx.doi.org/10.2174/156800911796798931
DOI https://dx.doi.org/10.2174/156800911796798931 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Proteomics to the Discovery of Cancer Biomarkers
Current Cancer Therapy Reviews Selective Peroxisome Proliferator-Activated Receptor-γ Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance
Recent Patents on Cardiovascular Drug Discovery Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews A Sialic Acid-Specific Lectin from the Mushroom Paecilomyces Japonica that Exhibits Hemagglutination Activity and Cytotoxicity
Protein & Peptide Letters Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies Serine Protease Inhibitor Kazal Type 1 (SPINK1): Beyond the Trypsin Inhibitor
Current Enzyme Inhibition Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention
Current Topics in Medicinal Chemistry Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Biologically Active Phytochemicals: A Brief Appraisal
Current Traditional Medicine Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Medicinal Treatments of Cholesterol Gallstones: Old, Current and New Perspectives
Current Medicinal Chemistry The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Insights on Antimicrobial Resistance, Biofilms and the Use of Phytochemicals as New Antimicrobial Agents
Current Medicinal Chemistry Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Current Drug Metabolism Extracellular HSP90: An Emerging Target for Cancer Therapy
Current Signal Transduction Therapy Squalamine as an Example of a New Potent Antimicrobial Agents Class: A Critical Review
Current Medicinal Chemistry